MX2020005370A - Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas. - Google Patents

Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas.

Info

Publication number
MX2020005370A
MX2020005370A MX2020005370A MX2020005370A MX2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
gvhd
defensins
versus
Prior art date
Application number
MX2020005370A
Other languages
English (en)
Inventor
Peter Nordkild
Original Assignee
Defensin Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defensin Therapeutics Aps filed Critical Defensin Therapeutics Aps
Publication of MX2020005370A publication Critical patent/MX2020005370A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para tratamiento y/o prevención de enfermedad aguda así como crónica de injerto contra hospedero (GVHD), y en particular a métodos para disminuir la mortalidad y especialmente incrementar la supervivencia a largo plazo; complicaciones agudas asociadas con GVHD tal como diarrea, pérdida de peso y sepsis tomando como base la normalización de la microbiota del intestino, hígado, pulmón y piel y la defensa de la mucosa; reequilibrio del sistema inmune con normalización de la producción de citoquina de IFN-?, TNF-a, Il-4, IL-5, IL-6, IL-8, IL-9, IL-10 e IL-13 y la prevención y/o tratamiento de tormenta de citoquinas; complicaciones crónicas asociadas con GVHD tales como bronquiolitis obliterante y escleroderma, el método comprende la administración oral, subcutánea, intrapulmonar y/o dérmica/transdérmica de una o más defensinas de mamífero que se seleccionan a partir del grupo de a- defensinas y ß-defensinas en un paciente que ha recibido o que está a punto de recibir un transplante alogénico de células madre hematopoyéticas.
MX2020005370A 2017-11-24 2018-11-21 Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas. MX2020005370A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17203527 2017-11-24
EP18191954 2018-08-31
PCT/EP2018/082022 WO2019101773A2 (en) 2017-11-24 2018-11-21 Prevention and treatment of graft-versus-host-disease with defensins

Publications (1)

Publication Number Publication Date
MX2020005370A true MX2020005370A (es) 2020-10-19

Family

ID=64308771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005370A MX2020005370A (es) 2017-11-24 2018-11-21 Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas.

Country Status (13)

Country Link
US (1) US20200291082A1 (es)
EP (1) EP3713590A2 (es)
JP (1) JP7423523B2 (es)
KR (1) KR20200097251A (es)
CN (1) CN111741762A (es)
AU (1) AU2018371948A1 (es)
BR (1) BR112020010180A2 (es)
CA (1) CA3083315A1 (es)
MX (1) MX2020005370A (es)
RU (1) RU2020116903A (es)
SG (1) SG11202004207VA (es)
WO (1) WO2019101773A2 (es)
ZA (1) ZA202002669B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR20230112561A (ko) * 2022-01-20 2023-07-27 가톨릭대학교 산학협력단 간이식환자 장내균총 분석과 이를 통한 이식상태 모니터링과 면역조절 테라그노시스 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US20060115480A1 (en) * 2002-12-19 2006-06-01 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
ES2904673T3 (es) 2008-02-01 2022-04-05 Ascendis Pharma As Profármaco que comprende un conjugado de fármaco-enlazador.
NZ587901A (en) * 2008-03-13 2012-11-30 Immuron Ltd Immuno-modulating compositions for the treatment of immune-mediated disorders
KR20110092325A (ko) 2008-07-18 2011-08-17 노보자임스 아데니움 바이오테크 에이/에스 포유류 베타 방어소를 이용한 염증성 장질환의 치료
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
JP6219277B2 (ja) * 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
CN107249609A (zh) * 2014-11-25 2017-10-13 纪念斯隆-凯特琳癌症中心 肠道微生物群和gvhd
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用
KR20180121489A (ko) * 2016-01-26 2018-11-07 디펜신 테라퓨틱스 에이피에스 장내 미생물을 조절하는 방법

Also Published As

Publication number Publication date
RU2020116903A3 (es) 2022-04-08
CA3083315A1 (en) 2019-05-31
EP3713590A2 (en) 2020-09-30
ZA202002669B (en) 2021-05-26
WO2019101773A2 (en) 2019-05-31
US20200291082A1 (en) 2020-09-17
SG11202004207VA (en) 2020-06-29
AU2018371948A1 (en) 2020-06-11
CN111741762A (zh) 2020-10-02
JP7423523B2 (ja) 2024-01-29
KR20200097251A (ko) 2020-08-18
JP2021504348A (ja) 2021-02-15
RU2020116903A (ru) 2021-12-24
BR112020010180A2 (pt) 2021-01-12
WO2019101773A3 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
EP4218807A3 (en) Zika virus vaccine
MY155137A (en) Compounds that expand hematopoietic stem cells
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
MX2020005370A (es) Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas.
WO2016030760A3 (en) Treatment of inflammation, respiratory tract infections and cystic fibrosis
JP2014527821A5 (es)
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
NZ587615A (en) Activation of innate and adaptive immune responses by a ginseng extract
MX2016013993A (es) Extracto de semilla de uva chardonnay.
JP2015517520A5 (es)
WO2017087754A3 (en) Compositions and methods of mechanically inducing tissue regeneration
MY167069A (en) Antigen peptide and use thereof
IN2014DN05784A (es)
WO2019059572A3 (ko) 홍어 껍질 유래의 신규한 항균 펩타이드 및 이의 용도
MX2020002551A (es) Metodos, composiciones y celulas para preparar proteina surfactante d (sp-d).
TW201613621A (en) Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof
SA518400776B1 (ar) تركيبة للعناية بالبشرة وطريقتها
Wang et al. High dose lipopolysaccharide triggers polarization of mouse thymic Th17 cells in vitro in the presence of mature dendritic cells
MY176907A (en) Chardonnay grape seed extract
Shin The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation? Comment on: Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 2013, 33 (2): 273–6
LT2014112A (lt) Iš normalių audinių gautos ksenogeninės vakcinos, skirtos pažeisti imuninės sistemos su navikais susijusių antigenų toleravimą
Wang et al. Human umbilical cord blood mononuclear cell transplantation for treatment of radioactive premature ovarian failure in nude mice
Gu et al. CD39hi nature regulatory T cells are stable under inflammation condition and preventing xeno-GVHD
Hansson et al. Macrophages Sources Of IL-22 Protein In Mouse Lungs Exposed To Peptidoglycan Or IL-23